The US FDA has authorized Jascayd (nerandomilast) tablets for the therapy of progressive pulmonary fibrosis (PPF) in adults, in keeping with Boehringer Ingelheim.
The authorization is the second FDA approval for Jascayd, after the drug was authorized to deal with idiopathic pulmonary fibrosis (IPF) in October 2025.
This represents a brand new therapy possibility within the US for this debilitating lung situation, with Jascayd being the primary and solely preferential phosphodiesterase 4B (PDE4B) inhibitor with immunomodulatory and antifibrotic results authorized on this indication.1,5 The FDA approval relies on outcomes from the pivotal Section III FIBRONEER-ILD scientific trial, the most important scientific trial program in PPF up to now. Outcomes confirmed that Jascayd successfully slowed lung perform decline in PPF with comparable everlasting discontinuation charges to placebo.
“Progressive pulmonary fibrosis is linked to underlying scientific ILD diagnoses together with autoimmune ILDs – which could be brought on by issues like rheumatoid arthritis or systemic sclerosis – in addition to hypersensitivity pneumonitis, amongst different situations,” mentioned Shervin Assassi, MD, Prof., Director of Rheumatology, McGovern Medical Faculty, UTHealth Houston. “These underlying situations typically result in the lungs being missed, but lung scarring could result in debilitating and irreversible impression on lung perform. This could have a detrimental impact on sufferers’ lives and highlights the necessity for brand spanking new therapy choices that may assist scale back the decline in lung perform, as has been noticed with Jascayd.”
The first endpoint in FIBRONEER-ILD was absolutely the change from baseline in Pressured Very important Capability (FVC), a measure of lung perform, in mL at Week 52. Jascayd demonstrated a considerably smaller discount in FVC decline from baseline in comparison with placebo.5 Particularly, the adjusted imply decline in absolute change from baseline in FVC in sufferers receiving Jascayd 18 mg or 9 mg was -86 mL and -69 mL, respectively, versus -152 mL within the placebo group.5 The respective therapy distinction in contrast with the placebo group was 65 mL (95% CI: 30, 101) and 83 mL (95% CI: 48, 118).5 The commonest opposed reactions in sufferers with PPF handled with Jascayd had been usually in keeping with these noticed in sufferers with IPF.5
“Progressive pulmonary fibrosis is a life-threatening situation with a excessive unmet medical want. The U.S. approval of JASCAYD is a vital step ahead to assist gradual lung perform decline for folks residing with PPF, offering a brand new, well-tolerated therapy possibility,” mentioned Shashank Deshpande, Chairman of the Board of Managing Administrators and Head of Human Pharma at Boehringer Ingelheim. “My gratitude goes to sufferers, investigators and our groups whose dedication made this milestone potential. We’ll now work carefully with stakeholders to allow entry and work tirelessly to make sure sufferers all over the world can profit from JASCAYD as rapidly as potential.”
“Individuals residing with progressive pulmonary fibrosis typically carry a heavy burden that others don’t all the time see,” mentioned Scott Staszak, President and CEO of the Pulmonary Fibrosis Basis. “A progressive illness situation course of like PPF can worsen lung perform rapidly, and sufferers have been eagerly awaiting extra therapy choices. The FDA approval of JASCAYD for PPF is a welcomed milestone for the neighborhood.”
